What is the research status of stem cells in China?

Because the key technology of stem cell research has only been broken for more than ten years, and China's own research level is not bad, China and western countries are almost on the same starting line. In this field, China is most likely to make original scientific contributions. In fact, the research and application of stem cells in China do have a certain foundation. As early as 1960s, China began to study bone marrow transplantation. By the end of 1970s and the beginning of 1980s, clinical bone marrow transplantation was carried out to treat hematological diseases. Since 1990s, in addition to bone marrow transplantation, stem cell transplantation of peripheral blood and umbilical cord blood has been gradually applied to the treatment of hematological diseases and tumors.

In 2009, the national bio-industrial base stem cell and regenerative medicine industrialization project was officially launched in China Medical City, Taizhou City, Jiangsu Province. Jiangsu stem cell and biotherapy technology service platform and umbilical cord mesenchymal stem cell storage business of Jiangsu stem cell bank were launched simultaneously. The industrialization project is undertaken by Jiangsu Beike Biotechnology Co., Ltd., a wholly-owned subsidiary of Shenzhen Beike Biotechnology Co., Ltd., and is responsible for the overall operation.

The national bio-industrial base-stem cell and regenerative medicine industrialization project is an industrialization expansion based on Jiangsu stem cell bank, including four centers: stem cell technology transformation center, testing center, Jiangsu stem cell bank phase II project and stem cell clinical technical service center. It is a comprehensive stem cell industrialization base integrating stem cell technology transformation, stem cell storage and application. Among them, the second phase of Jiangsu stem cell bank will be built in strict accordance with American GMP and GTP standards. Upon completion, the designed storage capacity will reach 6.5438+0 million copies, making it the largest and world-class comprehensive stem cell bank in Asia. The Bank will further expand the stem cell preservation business from umbilical cord mesenchymal stem cells and other sources, and continue to invest a lot of R&D power in iPS cells, so as to provide high-quality stem cell sources for the clinical application of stem cells and the treatment of various refractory diseases, and provide a strong guarantee for the health of the general public.